Company profile
Virpax Pharmaceuticals, Inc.
OTC: VRPX · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 10
v0.1 · 5/100 weight · pillars only
↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$12.1M
Employees
2
as of 2026-10-16
Market cap
$994
as of 2026-10-16
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$12.1M-$12.1M2024
Operating income-$12.1M-$12.1M2024
Total assets$1.6M$1.6M2024
Liabilities$2.5M$2.5M2024
Equity-$913.8k-$913.8k2024
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Virpax Pharmaceuticals, Inc.’s financial profile?
Virpax Pharmaceuticals, Inc. earned -$12.1M in FY2024 net income.
Peers · Healthcare
MSP Recovery, Inc.——PsyBio Therapeutics Corp——FusionPharm, Inc.——HLK Biotech Holding Group, Inc.——Sunset Island Group, Inc.——AXM Pharma, Inc.——Neighbors
Chester →Key facts
CEOJatinder Dhaliwal
SectorHealthcare
IndustryBiotechnology
HeadquartersBerwyn, PA
ExchangeOTC: VRPX
Employees2
IPO date2021-02-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.